Welcome everyone to the 2026 Annual Meeting of Shareholders of United Therapeutics Corporation, which as you can tell, is being held virtually again this year. Today is in fact, United Therapeutics' 30th birthday, and we're kicking off our celebrations with this annual meeting. My name is Paul A. Mahon, and I'm Executive Vice President, General Counsel, and Corporate Secretary of United Therapeutics. I'm actually in the room where it happened 30 years ago today, right here, where I faxed our articles of incorporation to Delaware exactly at 1:00 P.M. on June 26, 1996. With the history and the context aside, let's start with some introductions. Those present virtually at this meeting include Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer, James Edgemond, our Chief Financial Officer and Treasurer, and John Hess, our Deputy General Counsel and Assistant Corporate Secretary. Joining us this morning are most of the members of our Board of Directors, including Christopher Patusky, our Lead Independent Director and Vice Chair of United Therapeutics, and Chris Causey, the Chairperson of our Nominating and Governance Committee. I am happy to report that we also have David Spiegel with us representing our independent audit firm, Ernst & Young, and we are joined by Jim Rate, who is once again serving as our duly appointed Inspector of Elections on behalf of Broadridge Financial Solutions. We are certain at United Therapeutics, there is no finer Inspector of Elections in the election inspector industry, and we are delighted to ride with him again this year. Finally, a special shout-out to our team at Broadridge Financial Solutions, who once again have expertly delivered all the solutions and support for this virtual meeting. We especially want to thank the amazing, spectacular, and fun Regina Cobb, our impresario of this meeting, the virtual impresario. Ross, our operator, Sina Kwanon, our tech-talented technical host, Brendan, and our vigilant and responsive Broadridge Relationship Manager, Scott Raymond. Let's call this thing to order. I'm pleased to do that. I will call the meeting to order. I will serve as Chairperson of this meeting and my still long-suffering colleague and friend, John Hess, will serve as Secretary of this meeting. The agenda and rules of conduct for this morning's meeting are both available on this virtual meeting website. Please review these rules as they may contain important information, including how this meeting may be adjourned in the unlikely event that we experience any certain technical issues. If you have any questions regarding the matters being voted on this morning, you may enter them into the virtual meeting website prior to the closing of the polls for this morning's meeting. Please note that all questions must comply with our rules of conduct, which are also available on this virtual meeting website, and that only validated shareholders may ask questions in the designated field on the web portal. Out of consideration for others, we ask that you please limit yourself to one question, and please note that no one attending this meeting via the webcast or telephone is permitted to use any recording device. Also, it would be remiss of me not to mention that our remarks this morning may include forward-looking statements representing our expectations or beliefs regarding future events. Of course, these statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including our Forms 10-K and 10-Q, contain additional information on these risks and uncertainties, and we assume no obligation to update these forward-looking statements. I'd like to begin by asking our Secretary for a report on the United Therapeutics shareholders entitled to vote at this meeting. John, what say you? Thank you, Mr. Chairperson. The notice of meeting and proxy materials were mailed to all shareholders on or about April 29th, 2026. I have received the preliminary report from our Inspector of Elections, I can report that there are here represented virtually or by proxy over 37 million shares of United Therapeutics common stock, representing over 88% of the total issued and outstanding shares of the company. Oh, that's perfect, John. Thank you. Notice has been given to our shareholders in accordance with our bylaws, I can now declare that there is a quorum present that this meeting is duly called and ready for the transaction of business. The time is now 10:35 A.M. on June 26th, 2026, I declare the polls open on all four proposals on this morning's agenda. The polls will be closed to voting after we go through the matters upon which to be voted. Please note that shareholders who have sent in proxies or voted via telephone or the internet and who do not wish to change their vote, do not need to take any further action. Let's look at what we're voting on. As indicated in the proxy materials provided to our shareholders for this meeting and on the agenda posted to this virtual meeting website, we have four matters on which the shareholders will be voting this morning. The first item is the election of our directors. The following 12 individuals have been nominated to serve one-year terms until our 2027 Annual Meeting of Shareholders, or until their successors are duly elected and qualified. They are Mr. Christopher Causey, Mr. Richard Giltner, Mr. Ray Kurzweil, Ms. Jan Malcolm, Dr. Linda Maxwell, Professor Nilda Mesa, Dr. Judy Olian, Mr. Christopher Patusky, Dr. Martine Rothblatt, Dr. Louis Sullivan, Governor Tommy Thompson, and Dr. Kevin Tracey. The second item for voting this morning is an advisory resolution to approve executive compensation. The third item is the approval of the United Therapeutics Corporation 2026 Stock Incentive Plan. Finally, the fourth and final item for voting this morning is the ratification of Ernst & Young LLP as United Therapeutics' independent registered public accounting firm for 2026. I note that our board of directors has recommended that our shareholders vote for each of these director nominees and proposals. John, have you received any questions from shareholders during this meeting related to these four items on which we will be voting? Mr. Chairperson, we've received no questions at this morning's meeting. Well, thank you, John. There being no questions relating to the four items, I would like to note that the time is now 10:37 A.M. on June 26th, 2026, and I now declare the polls closed. Let's flip to the results. With the vote tabulated, I'd like to call for a report from our Secretary on the results of our election, which have been compiled from all the votes submitted prior to now, prior to closing the polls. John? Absolutely. Thank you, Paul. Based on the preliminary report of our Inspector of Elections, all 12 of the nominees for director have been elected, and each of the other three proposals have passed. A full tally of the votes cast on all matters before this meeting will be set forth in a current report on Form 8-K, which will be filed with the SEC within four business days. Thank you, John, as always, for a quick and accurate, complex calculation. I suspect there's smoke rising from your calculator on your desk, and we'll promptly replace that unit. There being no other business, the formal part of our 2026 Annual Meeting of Shareholders is now adjourned. We can move into a question and answer session if we have any questions. John, have we received any? There still are no questions waiting to be answered in our virtual portal. Since there are no questions in the queue, I don't think we're going to have a question and answer portion of our meeting. With that, we thank you for your virtual attendance this morning, for your continued support, for your best wishes on our 30th birthday. All the best, onwards. Goodbye. This now concludes the meeting. Thank you for joining, have a pleasant day.